Actively Recruiting

Phase 4
Age: 18Years - 75Years
All Genders
NCT06311942

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

Led by Chen Xiaoping · Updated on 2024-05-07

300

Participants Needed

1

Research Sites

247 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. What can be done to improve the surgical prognosis of this group of patients needs to be continuously explored.

CONDITIONS

Official Title

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 18 to 75 years
  • No prior local or systemic treatment for hepatocellular carcinoma
  • Child-Pugh liver function score of 7 or less
  • Eastern Cooperative Oncology Group performance status of 0 to 1
  • No serious diseases affecting heart, lungs, brain, or kidneys
  • Pathological diagnosis of hepatocellular carcinoma
  • Confirmation of VETC vascular pattern by CD34 immunohistochemical staining
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding women
  • Conditions interfering with drug absorption, distribution, metabolism, or clearance (e.g., severe vomiting, chronic diarrhea, intestinal obstruction)
  • History of gastrointestinal bleeding within 4 weeks or high risk of gastrointestinal bleeding not treated
  • Active infection
  • Significant clinical or laboratory abnormalities affecting safety assessment
  • Inability to follow study treatment or scheduled follow-up

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Wuhan, Hubei, China, 430000

Actively Recruiting

Loading map...

Research Team

W

WanGuang Zhang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. | DecenTrialz